Patent application title:

NUCLEIC ACID PROBE WITH SINGLE FLUOROPHORE LABEL BOUND TO INTERNAL CYTOSINE FOR USE IN LOOP MEDIATED ISOTHERMAL AMPLIFICATION

Publication number:

US20160273029A1

Publication date:
Application number:

15/032,011

Filed date:

2014-10-30

Abstract:

The disclosure relates to novel probes for use in LAMP detection methods. The probes contain a single fluorophore label bound to an internal cytosine residue of the probe. The probes are particularly useful in the detection of chlamydia and gonorrhea infections in a patient.

Inventors:

Interested in similar patents?

Get notified when new applications in this technology area are published.

Classification:

C12Q1/6825 »  CPC main

Measuring or testing processes involving enzymes, nucleic acids or microorganisms ; Compositions therefor; Processes of preparing such compositions involving nucleic acids; Hybridisation assays characterised by the detection means Nucleic acid detection involving sensors

C12Q1/689 »  CPC further

Measuring or testing processes involving enzymes, nucleic acids or microorganisms ; Compositions therefor; Processes of preparing such compositions involving nucleic acids; Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

C12Q1/6844 »  CPC further

Measuring or testing processes involving enzymes, nucleic acids or microorganisms ; Compositions therefor; Processes of preparing such compositions involving nucleic acids Nucleic acid amplification reactions

C12Q2600/16 »  CPC further

Oligonucleotides characterized by their use Primer sets for multiplex assays

C12Q1/68 IPC

Measuring or testing processes involving enzymes, nucleic acids or microorganisms ; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Description

FIELD OF THE INVENTION

The present invention relates to a probe for the detection of a nucleic acid, a method using said probe and a kit of parts. Preferably the probe of the invention is useful in a method for the detection of nucleic acids derived from Chlamydia trachomatis and/or Neisseria gonorrhoeae and may be used in the diagnosis of Chlamydia and/or Gonorrhoea infections.

REFERENCE TO SEQUENCE LISTING

A Sequence Listing submitted as an ASCII text file via EFS-Web is hereby incorporated by reference in accordance with 35 U.S.C. §1.52(e). The name of the ASCII text file for the Sequence Listing is 23109675_1. TXT, the date of creation of the ASCII text file is Apr. 12, 2016, and the size of the ASCII text file is 17.3 KB.

BACKGROUND OF THE INVENTION

Nucleic acid amplification is one of the most valuable tools in the life sciences field, including application-oriented fields such as clinical medicine, in which diagnosis of infectious diseases, genetic disorders and genetic traits is particularly benefited. In addition to the widely used PCR-based detection (Saiki R. K., Scharf, S., Faloona, F., Mullis, K. B., Horn, G. T., Erlich, H. A. and Arnheim, N. (1985) Science, 230, 1350-1354), several amplification methods have been invented. Examples include nucleic acid sequence-based amplification (NASBA), self-sustained sequence replication (3SR) and loop-mediated isothermal amplification (LAMP). PCR uses heat denaturation of double-stranded DNA products to promote the next round of DNA synthesis. 3SR and NASBA eliminate heat denaturation by using a set of transcription and reverse transcription reactions to amplify the target sequence.

These methods can amplify target nucleic acids to a similar magnitude, all with a detection limit of less than 10 copies and within an hour or so. They require either a precision instrument for amplification or an elaborate method for detection of the amplified products due to poor specificity of target sequence selection. Despite the simplicity and the obtainable magnitude of amplification, the requirement for a high precision thermal cycler in PCR prevents this powerful method from being widely used, such as in private clinics as a routine diagnostic tool. In contrast, LAMP is a method that can amplify a few copies of DNA to over 100 in less than an hour under isothermal conditions and with greater specificity.

As with other molecular-probe based technologies identified above, loop-mediated isothermal amplification (LAMP) assays can be used to detect the presence of specific microorganisms in a sample. However, the detection methods are based on direct visual detection, turbidity or via a non-specific DNA intercalating dye. Direct visual measurement is end point measurement and is unable to provide real time analysis. Turbidity and non-specific intercalating dyes do provide real time analysis of amplification which occurs however this is non-specific i.e. all amplification is detected whether this is true positive amplification or false amplification due to mis-priming, cross specificity.

SUMMARY OF THE INVENTION

In accordance with a first aspect of the present invention there is provided a probe for isothermal nucleic acid amplification comprising an oligonucleotide probe sequence complementary to a region of a target nucleic acid sequence, wherein said oligonucleotide probe sequence has only one fluorophore ligand and which ligand is bound to an internal cytosine base and wherein said oligonucleotide probe sequence does not have a 3′ end terminator.

In a preferred embodiment to oligonucleotide probe sequence is a DNA sequence and the target nucleic acid sequence is a DNA sequence.

Preferably, fluorescence increases to indicate the presence of the target nucleic acid in a sample.

The cytosine base is preferably substantially centrally disposed along the oligonucleotide's length. There are particular benefits associated with labeling the probe internally at a cytosine base. The specificity of the DNA product amplified in an isothermal reaction may be confirmed using a melt curve analysis. However due to a large number of product variants generated in this reaction and a low resolution of melt curve analysis, using intercalating dyes like V13, it is very difficult to distinguish between specific and unspecific DNA products generated under isothermal conditions. Commonly used probes such as TaqManĀ® probe are not compatible with LAMP technology due to the strand displacement activity of BST polymerase. The probe of the invention is elongated and becomes incorporated into a DNA product during isothermal amplification, which allows for performing a melt curve analysis on the generated product. In the probe of the invention, the fluorophore is conjugated to an internal cytosine complementary to guanine in the antisense strand. Guanine affects the excitation state of many fluorophores resulting in a formation of unique melt curve signatures and allows distinguishing between specific and unspecific products generated under isothermal conditions.

The oligonucleotide does not contain a ddNTP at its 3′ end which enables incorporation of the labelled oligonucleotide into the amplicon. Thus, the 3′ end of the probe is not ā€œblockedā€.

The fluorophore may comprise any one or more selected from the following: FAM, JOE, TET, HEX, TAMRA, ROX, ALEXA and ATTO.

The probe may comprise the following sequence:

5′ Xn C*Xm 3′

Where n is >1, m is >3, X is nucleotide base; and * is a fluorophore. Preferably, the nucleotide base is selected from A, T, C and G. Preferably, n is more than 1 to 20 or less, more preferably more than 1 to 10 or less. Preferably, m is more than 3 to 20 or less, more preferably more than 3 to 10 or less. It is contemplated that all combinations of lengths of probe covered by the possible number of nucleotides that n or m make take by the preceding ranges are disclosed.

Preferably, the probe may comprise a sequence selected from any one of the following sequences:

SEQā€ƒIDā€ƒNO.ā€ƒ2:
TAAGATAAC[C-FAM]CCGCACGTGā€ƒ(CTā€ƒPB1-FAMā€ƒinternal)
SEQā€ƒIDā€ƒNO.ā€ƒ4:
GCGAACATAā€ƒ[C-ALEXA546] CAGCTATGATCAAā€ƒ(GCā€ƒporA7-
joeā€ƒloopF)ā€ƒ
or
SEQā€ƒIDā€ƒNO.ā€ƒ5:
ATGTTCAā€ƒ[C-JOE] CATGGCGGAGā€ƒ(GCā€ƒglnA7-ALEXA546
loopB).

The fluorescence is preferably increased when the oligonucleotide is incorporated into the target nucleic acid sequence which results in a change in the configuration of the amplicon-probe complex leading to an alteration of the fluorophore excitation state.

The cytosine bound to the fluorophore ligand is not disposed at or proximate to the 5′ or 3′ end. More preferably it is not disposed in the first 3 bases from either the 5′ or 3′ end. Preferably the cytosine bound to the fluorophore is disposed at the middle base of the probe.

In accordance with a further aspect of the present invention, there is provided an isothermal nucleic acid amplification probe as described hereinabove.

In accordance with a further aspect of the present invention, there is provided a loop-mediated isothermal amplification probe as described above.

Methods and compositions for determining at least one target nucleic acid in a mixture of nucleic acids generally employ a probe, a hybridizing reagent, and one or more phosphate bond-forming enzymes associated with any required nucleotide triphosphates to form a nucleic acid chain.

These methods usually involve amplification, such as including the use of a promoter in conjunction with a RNA polymerase, a restriction site where only one strand is cleaved and is then displaced by extension with a DNA polymerase, or a circular hybridizing reagent, where concatenated repeats are produced. Detection of the amplified nucleic acid may take many forms but preferably via a fluorophore.

In accordance with a further aspect of the present invention, there is provided a method of detecting a target nucleic acid in a sample comprising:

a. amplifying a target nucleic acid in the sample to provide an amplified nucleic acid;
b. probing the amplified nucleic acid with a probe as described hereinabove; and
c. detecting the presence of a single or multiple target nucleic acids.

The target nucleic acid may be that from a micro-organism, fungi, yeast, virus, human, animal, plant etc. The target nucleic acid for LAMP is known to enable LAMP primers and appropriately specific probes to be synthesised. Thus, the presence or absence of said micro-organism, fungi, yeast, virus, human, animal or plant in a sample can be determined. Preferably the target nucleic acid is from Chlamydia trachomatis or Neisseria gonorrhoeae.

Preferably, fluorescence increases to indicate the presence of the target nucleic acid in a sample.

The process is isothermal, and allows for amplification in a single stage or sequential stages in a single vessel, where all of the reagents are compatible.

In a further aspect, the present invention provides a method of diagnosing Chlamydia and/or Gonorrhea in a patient, comprising

    • providing a sample derived from the patient;
    • adding one or more probes of the present invention to the sample; and
    • detecting the presence of a nucleic acid derived from Chlamydia trachomatis and/or Neisseria gonorrhoeae wherein an increase in the fluorescence of the probe indicates the presence of a Chlamydia trachomatis and/or Neisseria gonorrhoeae infection.

The sample may be treated by routine methods to enable the probe to bind with any target nucleotide present in the sample. Such treatment may include centrifuging and lysing the sample to release any target nucleic from the infecting microorganism.

In one embodiment, a single type of probe specific for a nucleic acid from either Chlamydia trachomatis or Neisseria gonorrhoeae is used in the method such that either only Chlamydia trachomatis or only Neisseria gonorrhoeae is detected in the sample.

In a preferred embodiment, at least two different probes are added to the sample wherein a first probe is labelled with a first fluorescent label and is specific for probing Chlamydia trachomatis nucleic acid and a second probe is labelled with a different fluorescent label to the first probe and is specific for probing Neisseria gonorrhoeae nucleic acid. In this embodiment, it is possible to simultaneously detect a Chlamydia and a Gonorrhea infection in a single sample derived from a patient.

In one aspect of the method of the invention, the sample from the patient may be a blood sample, urine sample, serum sample or saliva sample.

In accordance with a further aspect of the present invention there is provided a kit comprising a probe as described hereinabove, LAMP reaction buffer containing a polymerase enzyme, dNTPS and LAMP primers for the target.

In one embodiment a positive and negative control may be included in the kit. The reagents may be presented as wet reagents or in lyophilised form.

The buffer used in the method or kit of the invention comprises dNTPs at a concentration of from 1-10 mM, one or more salts at a concentration of from 2-20 mM, Tris pH8.8 at a concentration of from 10-100 mM, Trehalose at a concentration of from 10-100 mM, BST polymerase at an amount of from 1 U-12 U and 0.01%-1% 1,2 propanediol.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic of DNA probe of the invention.

FIGS. 2A to 2F shows amplification plots generated with the CT PB1 (FIG. 2A and FIG. 2D), GC glnA7 (FIG. 2B and FIG. 2E) and GC porA7 (FIG. 2C and FIG. 2F) primers in V6.21 buffer containing V13 (FIGS. 2A, 2B and 2C) or V6.21p buffer without V13 dye (FIGS. 2D, 2E and 2F).

FIGS. 3A and 3B are melt curve analyses of LAMP products generated with CT PB1 primers in the presence of CT PB1 internal probe conjugated with FAM. 100 pg per reaction of ATTC CT DNA standard was used as a positive control. A—normalized reporter plot, B—derivative reporter plot.

FIGS. 4A and B are melt curve analyses of LAMP product generated with GC glnA7 primers in the presence of GC glnA7 loop probe conjugated with JOE.

FIGS. 5A and 5B are melt curve analyses of LAMP product generated with GC porA7 primers in the presence of GC porA7 loop probe conjugated with ALEXA546. 100 pg per reaction of ATTC GC DNA standard was used as a positive control.

FIGS. 6A to 6D show the results of a test to confirm the DNA product specificity with a probe of the invention in loop mediated isothermal amplification.

FIG. 7 shows amplification plots generated with CT PB1 primers in V6.21 buffer containing V13 or V6.21p buffer without V13 dye but in the presence of CT PB1 terminal probe (complementary to loop region) with an internal C conjugated with FAM and 3′ terminator (3′ddC).

FIGS. 8A and 8B shows the amplification plots generated in V6.21p buffer containing ROX in the presence of CT PB1 primers and CT PB1 terminal probe with an internal cytosine conjugated with FAM (FIG. 8A), and universal primers and 3′UP probe with 3′ terminal cytosine conjugated with FAM (FIG. 8B).

FIGS. 9A to 9C show the amplification plots generated with CT PB1 primers in V6.21p buffer without V13 in the presence of CT PB1 internal probe with an internal C conjugated with FAM and a reference dye (ROX).

FIGS. 10A to 10C show the validation of CT PB1-FAM probe specificity. FIG. 10A shows amplification plots generated with CT PB1-FAM probe in the presence of CT DNA and CT primers.

FIGS. 11A and 11B shows the validation of CT PB1-FAM probe against APTIMA CT assay.

FIGS. 12A and 12B show the amplification plots generated in CT/GC multiplex with CT PB1-FAM+GC porA7-Alexa546 probes.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION

Abbreviations

CT—Chlamydia trachomatis
GC—Neisseria gonorrhoeae
GlnA7—Glutamine synthetase
PorA7—porin protein A7
LAMP—loop mediated isothermal amplification
PCR—polymerase chain reaction.

The present invention will now be described, by way of example only, with reference to the following examples and figures.

LAMP Reaction

V13 based detection of the target CT and GT DNA by LAMP was performed using LAMP V6.21 reaction buffer developed by the Applicant. Probe based detection of the target DNA was performed in V6.21p (without V13). The LAMP primer concentrations were as follows: CT PB1-0.8 μM FIP & BIP primer, 0.2 μM F3 & B3 and 0.4 μM Loop primers, GC porA7 and GC glnA7—2 μM FIP & BIP primer, 0.25 μM F3 & B3 and 0.5 μM Loop primers. All probes were used at a final concentration of 0.625 μM. LAMP reactions were run for 60 mins at a constant temperature of 63 C using AB17500 real-time PCR machine. Readouts of the fluorescent signal were obtained in SybrGreen/FAM, Joe or Cy3 channel as appropriate.

Probe Sequences

SEQā€ƒIDā€ƒNO.ā€ƒ1:
GTGCACGC[C-FAM]CCAATAGAAT
SEQā€ƒIDā€ƒNO.ā€ƒ2:
TAAGATAAC[C-FAM]CCGCACGTGā€ƒ(CTā€ƒPB1-FAMā€ƒinternal)
SEQā€ƒIDā€ƒNO.ā€ƒ3:
TCGAGCAA[C-FAM]CGCTGTGAC[ddC] (CTā€ƒPB1-FAM
terminal)
SEQā€ƒIDā€ƒNO.ā€ƒ4:
GCGAACATAā€ƒ[C-ALEXA546] CAGCTATGATCAAā€ƒ(GCā€ƒporA7-
joeā€ƒloopF)
SEQā€ƒIDā€ƒNO.ā€ƒ5:
ATGTTCAā€ƒ[C-JOE] CATGGCGGAGā€ƒ(GCā€ƒglnA7-ALEXA546
loopB)
or
SEQā€ƒIDā€ƒNO.ā€ƒ6:
CCAā€ƒGGGā€ƒTATā€ƒCTAā€ƒATCā€ƒCTGā€ƒTTTā€ƒGā€ƒ[C-FAM].

Target Sequences

The target DNA sequences used in the Examples are

SEQā€ƒIDā€ƒNo.ā€ƒ7:ā€ƒChlamydiaā€ƒtrachomatisā€ƒG/SotonG1ā€ƒplasmidā€ƒpSotonG1
completeā€ƒsequenceā€ƒ(GenBank:ā€ƒHE603235.1)
ā€ƒā€ƒā€ƒ1 tttgcaactcā€ƒttggtggtagā€ƒactttgcaacā€ƒtcttggtggtā€ƒagactttgcaā€ƒactcttggtg
ā€ƒā€ƒ61 gtagacttggā€ƒtcataatggaā€ƒcttttgttaaā€ƒaaaatttcttā€ƒaaaatcttagā€ƒagctccgatt
ā€ƒ121 ttgaatagctā€ƒttggttaagaā€ƒaaatgggctcā€ƒgatggctttcā€ƒcataaaagtaā€ƒgattgttctt
ā€ƒ181 aacttttgggā€ƒgacgcgtcggā€ƒaaatttggttā€ƒatctactttaā€ƒtctcatctaaā€ƒctagaaaaaa
ā€ƒ241 ttatgcgtctā€ƒgggattaactā€ƒttcttgtttcā€ƒtttagagattā€ƒctggatttatā€ƒcggaaacctt
ā€ƒ301 gataaaggctā€ƒatttctcttgā€ƒaccacagcgaā€ƒatctttgtttā€ƒaaaatcaagtā€ƒctctagatgt
ā€ƒ361 ttttaatggaā€ƒaaagtcgtttā€ƒcagaggcctcā€ƒtaaacaggctā€ƒagagcggcatā€ƒgctacatatc
ā€ƒ421 tttcacaaagā€ƒtttttgtataā€ƒgattgaccaaā€ƒgggatatattā€ƒaaacccgctaā€ƒttccattgaa
ā€ƒ481 agattttggaā€ƒaacactacatā€ƒtttttaaaatā€ƒccgagacaaaā€ƒatcaaaacagā€ƒaatcgatttc
ā€ƒ541 taagcaggaaā€ƒtggacagtttā€ƒtttttgaagcā€ƒgctccggataā€ƒgtgaattataā€ƒgagactattt
ā€ƒ601 aatcggtaaaā€ƒttgattgtacā€ƒaagggatccgā€ƒtaagttagacā€ƒgaaattttgtā€ƒctttgcgcac
ā€ƒ661 agacgatctaā€ƒttttttgcatā€ƒccaatcagatā€ƒttcctttcgcā€ƒattaaaaaaaā€ƒgacagaataa
ā€ƒ721 agaaaccaaaā€ƒattctaatcaā€ƒcatttcctatā€ƒcagcttaatgā€ƒgaagagttgcā€ƒaaaaatacac
ā€ƒ781 ttgtgggagaā€ƒaatgggagagā€ƒtatttgtttcā€ƒtaaaatagggā€ƒattcctgtaaā€ƒcaacaagtca
ā€ƒ841 ggttgcgcatā€ƒaattttaggcā€ƒttgcagagttā€ƒccatagtgctā€ƒatgaaaataaā€ƒaaattactcc
ā€ƒ901 cagagtacttā€ƒcgtgcaagcgā€ƒctttgattcaā€ƒtttaaagcaaā€ƒataggattaaā€ƒaagatgagga
ā€ƒ961 aatcatgcgtā€ƒatttcctgtcā€ƒtctcatcgagā€ƒacaaagtgtgā€ƒtgttcttattā€ƒgttctgggga
1021 agaggtaagtā€ƒcctctagtacā€ƒaaacacccacā€ƒaatattgtgaā€ƒtataattaaaā€ƒattatattca
1081 tattctgttgā€ƒccagaaaaaaā€ƒcacctttaggā€ƒctatattagaā€ƒgccatcttctā€ƒttgaagcgtt
1141 gtcttctcgaā€ƒgaggatttatā€ƒcgtacgcaaaā€ƒtatcatctttā€ƒgcggttgcgtā€ƒgtcccgtgac
1201 cttcattatgā€ƒtcggagtctgā€ƒagcaccctagā€ƒgcgtttgtacā€ƒtccgtcacagā€ƒcggttgctcg
1261 aagcacgtgcā€ƒggggttatctā€ƒtaaaagggatā€ƒtgcagcttgtā€ƒagtcctgcttā€ƒgagagaacgt
1321 gcgggcgattā€ƒtgccttaaccā€ƒccaccattttā€ƒtccggagcgaā€ƒgttacgaagaā€ƒcaaaacctct
1381 tcgttgaccgā€ƒatgtactcttā€ƒgtagaaagtgā€ƒcataaacttcā€ƒtgaggataagā€ƒttataataat
1441 cctcttttctā€ƒgtctgacggtā€ƒtcttaagctgā€ƒggagaaagaaā€ƒatggtagcttā€ƒgttggaaaca
1501 aatctgactaā€ƒatctccaagcā€ƒttaagacttcā€ƒagaggagcgtā€ƒttacctccttā€ƒggagcattgt
1561 ctgggcgatcā€ƒaaccaatcccā€ƒgggcgttgatā€ƒtttttttagcā€ƒtcttttaggaā€ƒaggatgctgt
1621 ttgcaaactgā€ƒttcatcgcatā€ƒccgtttttacā€ƒtatttccctgā€ƒgttttaaaaaā€ƒatgttcgact
1681 attttcttgtā€ƒttagaaggttā€ƒgcgctatagcā€ƒgactattcctā€ƒtgagtcatccā€ƒtgtttaggaa
1741 tcttgttaagā€ƒgaaatatagcā€ƒttgctgctcgā€ƒaacttgtttaā€ƒgtaccttcggā€ƒtccaagaagt
1801 cttggcagagā€ƒgaaactttttā€ƒtaatcgcatcā€ƒtaggattagaā€ƒttatgatttaā€ƒaaagggaaaa
1861 ctcttgcagaā€ƒttcatatccaā€ƒaagacaatagā€ƒaccaatctttā€ƒtctaaagacaā€ƒaaaaagatcc
1921 tcgatatgatā€ƒctacaagtatā€ƒgtttgttgagā€ƒtgatgcggtcā€ƒcaatgcataaā€ƒtaacttcgaa
1981 taaggagaagā€ƒcttttcatgcā€ƒgtttccaataā€ƒggattcttggā€ƒcgaatttttaā€ƒaaacttcctg
2041 ataagactttā€ƒtcgctatattā€ƒctaacgacatā€ƒttcttgctgcā€ƒaaagataaaaā€ƒtccctttacc
2101 catgaaatccā€ƒctcgtgatatā€ƒaacctatccgā€ƒcaaaatgtccā€ƒtgattagtgaā€ƒaataatcagg
2161 ttgttaacagā€ƒgatagcacgcā€ƒtcggtattttā€ƒtttatataaaā€ƒcatgaaaactā€ƒcgttccgaaa
2221 tagaaaatcgā€ƒcatgcaagatā€ƒatcgagtatgā€ƒcgttgttaggā€ƒtaaagctctgā€ƒatatttgaag
2281 actctactgaā€ƒgtatattctgā€ƒaggcagcttgā€ƒctaattatgaā€ƒgtttaagtgtā€ƒtcccatcata
2341 aaaacatattā€ƒcatagtatttā€ƒaaatacttaaā€ƒaagacaatggā€ƒattacctataā€ƒactgtagact
2401 cggcttgggaā€ƒagagcttttgā€ƒcggcgtcgtaā€ƒtcaaagatatā€ƒggacaaatcgā€ƒtatctcgggt
2461 taatgttgcaā€ƒtgatgctttaā€ƒtcaaatgacaā€ƒagcttagatcā€ƒcgtttctcatā€ƒacggttttcc
2521 tcgatgatttā€ƒgagcgtgtgtā€ƒagcgctgaagā€ƒaaaatttgagā€ƒcaatttcattā€ƒttccgctcgt
2581 ttaatgagtaā€ƒcaatgaaaatā€ƒccattgcgtaā€ƒgatctccgttā€ƒtctattgcttā€ƒgagcgtataa
2641 agggaaggctā€ƒtgatagtgctā€ƒatagcaaagaā€ƒctttttctatā€ƒtcgcagcgctā€ƒagaggccggt
2701 ctatttatgaā€ƒtatattctcaā€ƒcagtcagaaaā€ƒttggagtgctā€ƒggctcgtataā€ƒaaaaaaagac
2761 gagcagcgttā€ƒctctgagaatā€ƒcaaaattcttā€ƒtctttgatggā€ƒcttcccaacaā€ƒggatacaagg
2821 atattgatgaā€ƒtaaaggagttā€ƒatcttagctaā€ƒaaggtaatttā€ƒcgtgattataā€ƒgcagctaggc
2881 catctataggā€ƒgaaaacagctā€ƒttagctatagā€ƒacatggcgatā€ƒaaatcttgcgā€ƒgttactcaac
2941 agcgtagagtā€ƒtggtttcctaā€ƒtctctagaaaā€ƒtgagcgcaggā€ƒtcaaattgttā€ƒgagcggattg
3001 ttgctaatttā€ƒaacaggaataā€ƒtctggtgaaaā€ƒaattacaaagā€ƒaggggatctcā€ƒtctaaagaag
3061 aattattccgā€ƒagtggaagaaā€ƒgctggagaaaā€ƒcagttagagaā€ƒatcacattttā€ƒtatatctgca
3121 gtgatagtcaā€ƒgtataagcttā€ƒaatttaatcgā€ƒcgaatcagatā€ƒccggttgctgā€ƒagaaaagaag
3181 atcgagtagaā€ƒcgtaatatttā€ƒatcgattactā€ƒtgcagttgatā€ƒcaactcatcgā€ƒgttggagaaa
3241 atcgtcaaaaā€ƒtgaaatagcaā€ƒgatatatctaā€ƒgaaccttaagā€ƒaggtttagccā€ƒtcagagctaa
3301 acattcctatā€ƒagtttgtttaā€ƒtcccaactatā€ƒctagaaaagtā€ƒtgaggatagaā€ƒgcaaataaag
3361 ttcccatgctā€ƒttcagatttgā€ƒcgagacagcgā€ƒgtcaaatagaā€ƒgcaagacgcaā€ƒgatgtgattt
3421 tgtttatcaaā€ƒtaggaaggaaā€ƒtcgtcttctaā€ƒattgtgagatā€ƒaactgttgggā€ƒaaaaatagac
3481 atggatcggtā€ƒtttctcttcgā€ƒgtattacattā€ƒtcgatccaaaā€ƒaattagtaaaā€ƒttctccgcta
3541 ttaaaaaagtā€ƒatggtaaattā€ƒatagtaactgā€ƒccacttcatcā€ƒaaaagtcctaā€ƒtccaccttga
3601 aaatcagaagā€ƒtttggaagaaā€ƒgacctggtcaā€ƒatctattaagā€ƒatatctcccaā€ƒaattggctca
3661 aaatgggatgā€ƒgtagaagttaā€ƒtaggtcttgaā€ƒttttctttcaā€ƒtctcattaccā€ƒatgcattagc
3721 agctatccaaā€ƒagattactgaā€ƒccgcaacgaaā€ƒttacaaggggā€ƒaacacaaaagā€ƒgggttgtttt
3781 atccagagaaā€ƒtcaaatagttā€ƒttcaatttgaā€ƒaggatggataā€ƒccaagaatccā€ƒgttttacaaa
3841 aactgaattcā€ƒttagaggcttā€ƒatggagttaaā€ƒgcggtataaaā€ƒacatccagaaā€ƒataagtatga
3901 gtttagtggaā€ƒaaagaagctgā€ƒaaactgctttā€ƒagaagccttgā€ƒtaccatttagā€ƒgacatcaacc
3961 gtttttaataā€ƒgtggcaactaā€ƒgaactcgatgā€ƒgactaatggaā€ƒacacaaatagā€ƒtagaccgtta
4021 ccaaactcttā€ƒtctccgatcaā€ƒttaggatttaā€ƒcgaaggatggā€ƒgaaggtttaaā€ƒctgacgaaga
4081 aaatatagatā€ƒatagacttaaā€ƒcaccttttaaā€ƒttcaccatctā€ƒacacggaaacā€ƒataaaggatt
4141 cgttgtagagā€ƒccatgtcctaā€ƒtcttggtagaā€ƒtcaaatagaaā€ƒtcctactttgā€ƒtaatcaagcc
4201 tgcaaatgtaā€ƒtaccaagaaaā€ƒtaaaaatgcgā€ƒtttcccaaacā€ƒgcatcaaagtā€ƒatgcttacac
4261 atttatcgacā€ƒtgggtgattaā€ƒcagcagctgcā€ƒgaaaaagagaā€ƒcgaaaattaaā€ƒctaaggataa
4321 ttcttggccaā€ƒgaaaacttgtā€ƒtattaaacgtā€ƒtaacgttaaaā€ƒagtcttgcatā€ƒatattttaag
4381 gatgaatcggā€ƒtacatctgtaā€ƒcaaggaactgā€ƒgaaaaaaatcā€ƒgagttagctaā€ƒtcgataaatg
4441 tatagaaatcā€ƒgccattcagcā€ƒttggctggttā€ƒatctagaagaā€ƒaaacgcattgā€ƒaatttctgga
4501 ttcttctaaaā€ƒctctctaaaaā€ƒaagaaattctā€ƒatatctaaatā€ƒaaagagcgctā€ƒttgaagaaat
4561 aactaagaaaā€ƒtctaaagaacā€ƒaaatggaacaā€ƒagaatctattā€ƒaattaatagcā€ƒaggcttgaaa
4621 ctaaaaacctā€ƒaatttatttaā€ƒaagctcaaaaā€ƒtaaaaaagagā€ƒttttaaaatgā€ƒggaaattctg
4681 gtttttatttā€ƒgtataacactā€ƒgaaaactgcgā€ƒtctttgctgaā€ƒtaatatcaaaā€ƒgttgggcaaa
4741 tgacagagccā€ƒgctcaaggacā€ƒcagcaaataaā€ƒtccttgggacā€ƒaaaatcaacaā€ƒcctgtcgcag
4801 ccaaaatgacā€ƒagcttctgatā€ƒggaatatcttā€ƒtaacagtctcā€ƒcaataattcaā€ƒtcaaccaatg
4861 cttctattacā€ƒaattggtttgā€ƒgatgcggaaaā€ƒaagcttaccaā€ƒgcttattctaā€ƒgaaaagttgg
4921 gaaatcaaatā€ƒtcttgatggaā€ƒattgctgataā€ƒctattgttgaā€ƒtagtacagtcā€ƒcaagatattt
4981 tagacaaaatā€ƒcacaacagacā€ƒccttctctagā€ƒgtttgttgaaā€ƒagcttttaacā€ƒaactttccaa
5041 tcactaataaā€ƒaattcaatgcā€ƒaacgggttatā€ƒtcactcccagā€ƒtaacattgaaā€ƒactttattag
5101 gaggaactgaā€ƒaataggaaaaā€ƒttcacagtcaā€ƒcacccaaaagā€ƒctctgggagcā€ƒatgttcttag
5161 tctcagcagaā€ƒtattattgcaā€ƒtcaagaatggā€ƒaaggcggcgtā€ƒtgttctagctā€ƒttggtacgag
5221 aaggtgattcā€ƒtaagccctgcā€ƒgcgattagttā€ƒatggatactcā€ƒatcaggcgttā€ƒcctaatttat
5281 gtagtctaagā€ƒaaccagcattā€ƒactaatacagā€ƒgattgactccā€ƒaacaacgtatā€ƒtcattacgtg
5341 taggcggtttā€ƒagaaagcggtā€ƒgtggtatgggā€ƒttaatgccctā€ƒttctaatggcā€ƒaatgatattt
5401 taggaataacā€ƒaaatacttctā€ƒaatgtatcttā€ƒttttggaagtā€ƒaatacctcaaā€ƒacaaacgctt
5461 aaacaattttā€ƒtattggatttā€ƒttcttataggā€ƒttttatatttā€ƒagagaaaacaā€ƒgttcgaatta
5521 cggggtttgtā€ƒtatgcaaaatā€ƒaaaagaaaagā€ƒtgagggacgaā€ƒttttattaaaā€ƒattgttaaag
5581 atgtgaaaaaā€ƒagatttccccā€ƒgaattagaccā€ƒtaaaaatacgā€ƒagtaaacaagā€ƒgaaaaagtaa
5641 ctttcttaaaā€ƒttctcccttaā€ƒgaactctaccā€ƒataaaagtgtā€ƒctcactaattā€ƒctaggactgc
5701 ttcaacaaatā€ƒagaaaactctā€ƒttaggattatā€ƒtcccagactcā€ƒtcctgttcttā€ƒgaaaaattag
5761 aggataacagā€ƒtttaaagctaā€ƒaaaaaggcttā€ƒtgattatgctā€ƒtatcttgtctā€ƒagaaaagaca
5821 tgttttccaaā€ƒggctgaatagā€ƒacaacttactā€ƒctaacgttggā€ƒagttgatttgā€ƒcacaccttag
5881 ttttttgctcā€ƒttttaagggaā€ƒggaactggaaā€ƒaaacaacactā€ƒttctctaaacā€ƒgtgggatgca
5941 acttggcccaā€ƒatttttagggā€ƒaaaaaagtgtā€ƒtacttgctgaā€ƒcctagacccgā€ƒcaatccaatt
6001 tatcttctggā€ƒattgggggctā€ƒagtgtcagaaā€ƒataaccaaaaā€ƒaggcttgcacā€ƒgacatagtat
6061 acaaatcaaaā€ƒcgatttaaaaā€ƒtcaatcatttā€ƒgcgaaacaaaā€ƒaaaagatagtā€ƒgtggacctaa
6121 ttcctgcatcā€ƒatttttatccā€ƒgaacagtttaā€ƒgagaattggaā€ƒtattcatagaā€ƒggacctagta
6181 acaacttaaaā€ƒgttatttctgā€ƒaatgagtactā€ƒgcgctcctttā€ƒttatgacatcā€ƒtgcataatag
6241 acactccaccā€ƒtagcctaggaā€ƒgggttaacgaā€ƒaagaagctttā€ƒtgttgcaggaā€ƒgacaaattaa
6301 ttgcttgtttā€ƒaactccagaaā€ƒcctttttctaā€ƒttctagggttā€ƒacaaaagataā€ƒcgtgaattct
6361 taagttcggtā€ƒcggaaaacctā€ƒgaagaagaacā€ƒacattcttggā€ƒaatagctttgā€ƒtctttttggg
6421 atgatcgtaaā€ƒctcgactaacā€ƒcaaatgtataā€ƒtagacattatā€ƒcgagtctattā€ƒtacaaaaaca
6481 agcttttttcā€ƒaacaaaaattā€ƒcgtcgagataā€ƒtttctctcagā€ƒccgttctcttā€ƒcttaaagaag
6541 attctgtagcā€ƒtaatgtctatā€ƒccaaattctaā€ƒgggccgcagaā€ƒagatattctgā€ƒaagttaacgc
6601 atgaaatagcā€ƒaaatattttgā€ƒcatatcgaatā€ƒatgaacgagaā€ƒttactctcagā€ƒaggacaacgt
6661 gaacaaactaā€ƒaaaaaagaagā€ƒcggatgtcttā€ƒttttaaaaaaā€ƒaatcaaactgā€ƒccgcttctct
6721 agattttaagā€ƒaagacacttcā€ƒcttccattgaā€ƒactattctcaā€ƒgcaactttgaā€ƒattctgagga
6781 aagtcagagtā€ƒttggatcgatā€ƒtatttttatcā€ƒagagtcccaaā€ƒaactattcggā€ƒatgaagaatt
6841 ttatcaagaaā€ƒgacatcctagā€ƒcggtaaaactā€ƒgcttactggtā€ƒcagataaaatā€ƒccatacagaa
6901 gcaacacgtaā€ƒcttcttttagā€ƒgagaaaaaatā€ƒctataatgctā€ƒagaaaaatccā€ƒtgagtaagga
6961 tcacttctccā€ƒtcaacaacttā€ƒtttcatcttgā€ƒgatagagttaā€ƒgtttttagaaā€ƒctaagtcttc
7021 tgcttacaatā€ƒgctcttgcatā€ƒattacgagctā€ƒttttataaacā€ƒctccccaaccā€ƒaaactctaca
7081 aaaagagtttā€ƒcaatcgatccā€ƒcctataaatcā€ƒcgcatatattā€ƒttggccgctaā€ƒgaaaaggcga
7141 tttaaaaaccā€ƒaaggtcgatgā€ƒtgatagggaaā€ƒagtatgtggaā€ƒatgtcgaactā€ƒcatcggcgat
7201 aagggtgttgā€ƒgatcaatttcā€ƒttccttcatcā€ƒtagaaacaaaā€ƒgacgttagagā€ƒaaacgataga
7261 taagtctgatā€ƒttagagaagaā€ƒatcgccaattā€ƒatctgatttcā€ƒttaatagagaā€ƒtacttcgcat
7321 catatgttccā€ƒggagtttcttā€ƒtgtcctcctaā€ƒtaacgaaaatā€ƒcttctacaacā€ƒagctttttga
7381 actttttaagā€ƒcaaaagagctā€ƒgatcctccgtā€ƒcagctcatatā€ƒatatatttatā€ƒtatatatata
7441 tttatttaggā€ƒgatttgatttā€ƒtacgagagagā€ƒa
SEQā€ƒIDā€ƒNo.ā€ƒ8:ā€ƒNeisseriaā€ƒgonorrhoeaeā€ƒpartialā€ƒporAā€ƒgeneā€ƒforā€ƒclass
1ā€ƒouterā€ƒmembraneā€ƒprotein,ā€ƒisolateā€ƒGC3ā€ƒ(GenBank:ā€ƒHE681886.1)
ā€ƒā€ƒā€ƒ1 gccggcggcgā€ƒgcgcgacccgā€ƒttggggcaatā€ƒagggaatcctā€ƒttgtcggcttā€ƒggcaggcgaa
ā€ƒā€ƒ61 ttcggcacgcā€ƒtgcgcgccggā€ƒccgcgttgcgā€ƒaatcagtttgā€ƒacgatgccagā€ƒccaagccatt
ā€ƒ121 gatccttgggā€ƒacagcaacaaā€ƒtgatgtggctā€ƒtcgcaattggā€ƒgtattttcaaā€ƒacgccacgac
ā€ƒ181 gatatgccggā€ƒtttccgtacgā€ƒctacgactccā€ƒccggacttttā€ƒccggtttcagā€ƒcggcagcgtc
ā€ƒ241 caattcgttcā€ƒcggctcaaaaā€ƒcagcaagtccā€ƒgcctatacgcā€ƒcggctcattgā€ƒgactactgtg
ā€ƒ301 tataacactaā€ƒacggtactacā€ƒtactactttcā€ƒgttccggctgā€ƒttgtcggcaaā€ƒgcccggatcg
ā€ƒ361 gatgtgtattā€ƒatgccggtctā€ƒgaattacaaaā€ƒaatggcggttā€ƒttgccgggaaā€ƒctatgccttt
ā€ƒ421 aaatatgcgaā€ƒgacacgccaaā€ƒtgtcggacgtā€ƒaatgcttttgā€ƒagttgttcttā€ƒgctcggcagt
ā€ƒ481 gggagtgatgā€ƒaagccaaaggā€ƒtaccgatcccā€ƒttgaaaaaccā€ƒatcaggtacaā€ƒccgcctgacg
ā€ƒ541 ggcggctatgā€ƒgggaaggcggā€ƒcttgaatctcā€ƒgccttggcggā€ƒctcagttggaā€ƒtttgtctgaa
ā€ƒ601 aatgccgacaā€ƒaaaccaaaaaā€ƒcagtacgaccā€ƒgaaattgccgā€ƒccactgcttcā€ƒctaccgcttc
ā€ƒ661 ggtaatacagā€ƒtcccgcgcatā€ƒcagctatgccā€ƒcatggtttcgā€ƒactttgtcgaā€ƒacgcagtcag
ā€ƒ721 aaacgcgaacā€ƒataccagctaā€ƒtga
SEQā€ƒIDā€ƒNo.ā€ƒ9:ā€ƒNeisseriaā€ƒgonorrhoeaeā€ƒglutamineā€ƒsynthetaseā€ƒ(glnA)
gene,ā€ƒglnA-14ā€ƒallele,ā€ƒpartialā€ƒcdsā€ƒ(GenBank:ā€ƒAF520262.1)
ā€ƒā€ƒā€ƒ1 cccgctttgtā€ƒcgatttgcgcā€ƒttcaccgataā€ƒccaaaggcaaā€ƒgcagcaccacā€ƒtttaccgtgc
ā€ƒā€ƒ61 ctgcgcgcatā€ƒcgtgttggaaā€ƒgaccccgaagā€ƒagtggtttgaā€ƒaaacggaccgā€ƒgcgtttgacg
ā€ƒ121 gctcgtccatā€ƒcggcggctggā€ƒaaaggcattgā€ƒaggcttccgaā€ƒtatgcagctgā€ƒcgtcccgatg
ā€ƒ181 cgtccacagcā€ƒcttcgtcgatā€ƒcctttttatgā€ƒatgatgttacā€ƒcgtcgtcattā€ƒacctgcgacg
ā€ƒ241 tcatcgacccā€ƒtgccgacggtā€ƒcagggttacgā€ƒaccgcgacccā€ƒgcgctccatcā€ƒgcacgccgcg
ā€ƒ301 ccgaagcctaā€ƒtttgaaatctā€ƒtccggtatcgā€ƒgcgacaccgcā€ƒctatttcggcā€ƒcccgaacccg
ā€ƒ361 aattcttcgtā€ƒcttcgacggcā€ƒgtagaatttgā€ƒaaaccgacatā€ƒgcacaaaaccā€ƒcgttacgaaa
ā€ƒ421 tcacgtccgaā€ƒaagcggcgcgā€ƒtgggcaagcgā€ƒgcctgcatatā€ƒggacggtcaaā€ƒaacaccggcc
ā€ƒ481 accgccccgcā€ƒcgtcaaaggcā€ƒggctacgcgcā€ƒccgtcgcgccā€ƒgattgactgcā€ƒggtcaagatt
ā€ƒ541 tgcgctccgcā€ƒcatggtgaacā€ƒattttggaagā€ƒgactcggcatā€ƒcgaagtcgaaā€ƒgtccaccaca
ā€ƒ601 gcgaagtcggā€ƒtaccggcagcā€ƒcaaatggaaaā€ƒtcggcacccgā€ƒtttcgccactā€ƒttggtcaaac
ā€ƒ661 gcgccgaccaā€ƒaacccaagatā€ƒatgaaatacgā€ƒtcatccaaaaā€ƒcgttgcccacā€ƒaatttcggca
ā€ƒ721 aaaccgccacā€ƒctttatgcccā€ƒaaaccgattaā€ƒtgggcgacaaā€ƒcggcagcggtā€ƒatgcacgtcc
ā€ƒ781 accaatccatā€ƒttggaaagacā€ƒggtcaaaaccā€ƒtgttcgcaggā€ƒcgacggctatā€ƒgccggtttgt
ā€ƒ841 ccgataccgcā€ƒgctctactacā€ƒatcggcggcaā€ƒtcatcaaacaā€ƒcgccaaagccā€ƒctgaacgcga
ā€ƒ901 ttaccaatccā€ƒgtccaccaacā€ƒtcctacaaacā€ƒgcctcgtgccā€ƒgcactttgaaā€ƒgcaccgacca
ā€ƒ961 aattggcctaā€ƒttccgccaaaā€ƒaaccgttccgā€ƒcttccatccgā€ƒtatcccgtctā€ƒgtgaacagca
1021 gcaaggcgcgā€ƒccgcatcgaaā€ƒgcgcgtttccā€ƒccgacccgacā€ƒcgccaacccgā€ƒtatttggcat
1081 ttgccgccctā€ƒgctgatggccā€ƒggtttggacgā€ƒgcattcaaaaā€ƒcaaaatccatā€ƒccgggcgacc
1141 ctgccgataaā€ƒaaacctgtacā€ƒgacctgccgcā€ƒcggaagaagaā€ƒcgcgctcgtcā€ƒccgaccgtct
1201 gcgcttctttā€ƒggaagaagcaā€ƒcttgccgcccā€ƒtcaaggtcgaā€ƒccacgaattcā€ƒctgctgcgcg
1261 gcggcgtgttā€ƒcagcaaagacā€ƒtggatcgacaā€ƒgctacatcgcā€ƒctttaaagagā€ƒgaagatgtcc
1321 gccgcatccgā€ƒtatggcgccgā€ƒcacccgctggā€ƒaatttg

The primer sequences used in the LAMP reaction are as follows:

CT Plasmid

(SEQā€ƒIDā€ƒNo.ā€ƒ10)
F3 TCTACAAGAGTACATCGGTCA
(SEQā€ƒIDā€ƒNo.ā€ƒ11)
B3 TGAAGCGTTGTCTTCTCG
(SEQā€ƒIDā€ƒNo.ā€ƒ12)
FIP GCAGCTTGTAGTCCTGCTTGAGTCTTCGTAACTCGCTCC
(SEQā€ƒIDā€ƒNo.ā€ƒ13)
BIP TCGAGCAACCGCTGTGACCCTTCATTATGTCGGAGTCTG
(SEQā€ƒIDā€ƒNo.ā€ƒ14)
LF1 CGGGCGATTTGCCTTAAC
(SEQā€ƒIDā€ƒNo.ā€ƒ15)
LB1 TACAAACGCCTAGGGTGC

GC porA7

(SEQā€ƒIDā€ƒNo.ā€ƒ16)
F3 ACCAAAAACAGTACGACCGA
(SEQā€ƒIDā€ƒNo.ā€ƒ17)
B3 AAGTGCGCTTGGAAAAATCG
(SEQā€ƒIDā€ƒNo.ā€ƒ18)
FIPATGGGCATAGCTGATGCGCGAATTGCCGCCACTGCTTC
(SEQā€ƒIDā€ƒNo.ā€ƒ19)
BIP TCGACTTTGTCGAACGCAGTCAAATCGACACCGGCGATGA
(SEQā€ƒIDā€ƒNo.ā€ƒ20)
LoopF1 GCGAACATACCAGCTATGATCAA

GC glnA7

(SEQā€ƒIDā€ƒNo.ā€ƒ21)
F3 TCATATCTTGGGTTTGGTCG
(SEQā€ƒIDā€ƒNo.ā€ƒ22)
B3 CTGCATATGGACGGTCAAA
(SEQā€ƒIDā€ƒNo.ā€ƒ23)
FiP CGAAGTCCACCACAGCGAATTTGACCAAAGTGGCGAA
(SEQā€ƒIDā€ƒNo.ā€ƒ24)
BiP CTTCGATGCCGAGTCCTTCCGATTGACTGCGGTCAAGAT
(SEQā€ƒIDā€ƒNo.ā€ƒ25)
LF CAAATGGAAATCGGCACCC
(SEQā€ƒIDā€ƒNo.ā€ƒ26)
LB ATGTTCACCATGGCGGAG

Buffer

The Applicant has developed a buffer system for use with the probes of the invention and is designated V6.21 (or V6.21p without V13 dye present) in the following Examples. The concentrations of the buffer components are after buffer reconstitution:

V6.21

4-10 mM dNTP's, 10 mM salt, 30 mM Tris pH8.8, 30 mM Trehalose, 1-8 U Bst polymerase, Dye and 0.05% propanediol.

V6.21p

4-10 mM dNTP's, 10 mM salt, 30 mM Tris pH8.8, 30 mM Trehalose, 1-8 U Bst polymerase, and 0.05% propanediol.

PCR

CT/GC detection in clinical samples by real-time PCR was performed using APTIMA CT/GC multiplex (Gen-Probe) according to the manufacturer's instructions.

Agarose Gel Electrophoresis

DNA electrophoresis was conducted in 1% agarose gel 1ƗTAE buffer at 100V. LAMP DNA products were vitalized with GelRed (Invitrogen) with transilluminator.

V6.21 and V6.21p buffer were developed by the Applicant. LAMP primers were obtained from Eurofins. Fluorophore-labelled oligonucleotides were purchased from Integrated DNA technologies. Tris buffer, agarose gel and PCR grade water were purchased from Sigma. CT and GC DNA standards were obtained from ATCC.

FIGURES

FIG. 1 is a schematic of DNA probe of the invention. The probe consists of an oligonucleotide with an internal cytosine conjugated with a defined fluorophore. The probe may be complementary to the internal region of the amplicon flanked by Flp and Blp primers or it may be a modified LoopF or LoopB primer internally labeled with a fluorophore.

Example 1

FIGS. 2A to 2F shows amplification plots generated with the CT PB1 (FIG. 2A and FIG. 2D), GC glnA7 (FIG. 2B and FIG. 2E) and GC porA7 (FIG. 2C and FIG. 2F) primers in V6.21 buffer containing V13 (FIGS. 2A, 2B and 2C) or V6.21p buffer without V13 dye (FIGS. 2D, 2E and 2F). The target sequences shown in SEQ ID NOs. 7 to 9 with CT PB1 internal probe conjugated with FAM, GC glnA7 loop probe conjugated with Joe and GC porA7 loop probe conjugated with Alexa546 respectively. All reactions were performed for 60 mins at a constant temperature of 63 C with AB17500 machine.

Example 2

FIGS. 3A and 3B are melt curve analyses of LAMP products generated with CT PB1 primers in the presence of CT PB1 internal probe conjugated with FAM. 100 pg per reaction of ATTC CT DNA standard was used as a positive control. A—normalized reporter plot, B—derivative reporter plot. Melt curve plots were generated based on the readouts in FAM channel with AB17500 machine.

Example 3

FIGS. 4A and B are melt curve analyses of LAMP product generated with GC glnA7 primers in the presence of GC glnA7 loop probe conjugated with JOE. 100 pg per reaction of ATTC GC DNA standard was used as a positive control. FIG. 4A shows a normalized reporter plot and FIG. 4B shows a derivative reporter plot. Melt curve plots were generated based on the readouts in JOE channel with AB17500 machine.

Example 4

FIGS. 5A and 5B are melt curve analyses of LAMP product generated with GC porA7 primers in the presence of GC porA7 loop probe conjugated with ALEXA546. 100 pg per reaction of ATTC GC DNA standard was used as a positive control. FIG. 5A shows a normalized reporter plot, FIG. 4B shows a derivative reporter plot. Melt curve plots were generated based on the readouts in Cy3 channel with AB17500 machine.

Example 5

FIGS. 6A to 6D show the results of a test to confirm the DNA product specificity with a probe of the invention in loop mediated isothermal amplification. The late amplification time of the false positives (more than 30 mins after the lowest target DNA concentration detectable in the LAMP reaction (100 fg GC DNA) indicates that the unspecific amplification may be a result of primer dimer formation. The standard melt curve analysis does not allow to distinguish between the specific and unspecific product in this LAMP reaction, but the unspecific product may be recognized with the probe of the invention. GC DNA was amplified with GC porA7 primers and visualized with V13 dye or GC porA7-ALEXA546 probe as appropriate.

Example 6

FIG. 7 shows the amplification plots generated with CT PB1 primers in V6.21 buffer containing V13 or V6.21p buffer without V13 dye but in the presence of CT PB1 terminal probe (complementary to loop region) with an internal C conjugated with FAM and 3′ terminator (3′ddC). Despite a successful amplification of the target DNA confirmed by excitation of the V13 dye in the control reaction, CT PB1 probe with 3′ terminator did not generate a positive signal.

Example 7

FIGS. 8A and 8B shows the amplification plots generated in V6.21p buffer containing ROX in the presence of CT PB1 primers and CT PB1 terminal probe with an internal cytosine conjugated with FAM (FIG. 8A), and universal primers and 3′UP probe with 3′ terminal cytosine conjugated with FAM (FIG. 8B). The first line represents signals generated by ROX, and the second line corresponds to the signal generated in the FAM channel. Binding of the probe with an internally labeled C to the target DNA results in FAM excitation. Binding of the probe with a 3′ end C labeled to the target does not alter the FAM excitation state.

Example 8

FIGS. 9A to 9C show the amplification plots generated with CT PB1 primers in V6.21p buffer without V13 in the presence of CT PB1 internal probe with an internal C conjugated with FAM and a reference dye (ROX). FIG. 9A show raw data, readouts from the FAM channel in the first line and from the ROX channel in a second line. FIG. 9B shows amplification plots (generated in FAM channel) normalized to ROX. FIG. 9C shows derivative reporter melt curve plots.

Example 9

FIGS. 10A to 10C show the validation of CT PB1-FAM probe specificity. FIG. 10A shows amplification plots generated with CT PB1-FAM probe in the presence of CT DNA and CT primers. As a control, two sets of reactions were performed where unspecific genes, GC glnA7 and GC porA7 were amplified with the corresponding LAMP primers in the presence of CT PB1-FAM probe. In V6.21p buffer the amplification plots in the presence of CT PB1 probe in the FAM channel were generated only when CT DNA was present in the reaction and no signal was generated when unspecific genes (GC glnA7 and GC porA7) were amplified. No signal was also generated when an unspecific probe was used in a reaction where CT DNA was amplified with CT primers. FIG. 10C shows data obtained in an analogous experiment but conducted in V6.21 buffer containing an intercalating dye V31. FIG. 10C shows DNA products generated in the experiment described in FIG. 10A.

Example 10

FIGS. 11A and 11B shows the validation of CT PB1-FAM probe against APTIMA CT assay. Fifty clinical samples confirmed to be positive (n=29) (FIG. 11A) or negative (n=21) (FIG. 11B) for CT were tested in V6.21p buffer with CT PB1-FAM probe. Out of 50 samples 24 tested negative (FIG. 11A) and 26 tested positive (FIG. 11B) for CT with CT PB1-FAM probe. There was 86% agreement between the Aptima and CT PB-FAM tests.

Example 11

FIGS. 12A and 12B show the amplification plots generated in CT/GC multiplex with CT PB1-FAM+GC porA7-Alexa546 probes. CT and GC DNA was amplified in separate reactions or in conjugation in V6.21p buffer in the presence of CT PB1-FAM and GC porA7-Alexa546 probes. The readouts were taken in Cy3 (FIG. 12A) and FAM (FIG. 12B) channels. The experiment revealed that two DNA targets may be amplified and detected in a simultaneous reaction with FAM and Alexa546 labeled probes and that there was no cross reactivity between CT PB1 and GC porA7 primers and probes.

Example 12

Table1 shows a comparison between V13 LAMP for CT and GC, CT/GC Aptima and CT/GC multiplex (CT PB1-FAM+GC porA7-Alexa546). DNA extracted from 136 clinical samples was tested with CT/GC Aptima multiplex, CT PB1 and GC porA7 primers in V6.21 buffer containing V13 or in a multiplex reaction in v6.21p buffer in the presence of CT PB1 and GC porA7 primers and CT PB1-FAM and GC porA7-Alexa546 probes. In a control experiment the samples were also tested in a simplex reaction with GC glnA7-joe probe. The table shows the agreement scores between the tests.

TABLE 1
Comparison between V13-based LAMP for CT and GC, CT/GC
Aptima multiplex and CT/GC MAST multiplex (CT PB1-FAM +
GC porA7-Alexa546). (Test on 136 clinical samples)
Tests compared Agreement score
CT LAMP vs CT PB1-FAM in multiplex 92%
GC LAMP vs. GC porA7-Alexa546 in multiplex 94%
CT in multiplex vs CT Aptima 83%
GC in multiplex vs GC Aptima 86%

Claims

1. A probe for isothermal nucleic acid amplification comprising an oligonucleotide probe sequence complementary to a region of a target nucleic acid sequence, wherein said oligonucleotide probe sequence has only one fluorophore label and which label is bound to an internal cytosine base and wherein said oligonucleotide probe sequence does not have a 3′ end terminator.

2. The probe of claim 1, wherein the cytosine base is substantially centrally disposed along the oligonucleotide's length except for positions 1-3 at the 3′ end and position 1 at the 5′ end.

3. The probe of claim 1, wherein the oligonucleotide probe sequence is a DNA sequence and the target nucleic acid sequence is a DNA sequence.

4. The probe of claim 1, wherein the fluorophore comprises any one or more selected from the group consisting of: FAM, JOE, TET, HEX, TAMRA, ROX, ALEXA and ATTO.

5. The probe of claim 1, comprising the following sequence:

5′ Xn C*Xm 3′

wherein n is >1, m>3, X is nucleotide base; and * is fluorophore.

6. The probe of claim 5, wherein the nucleotide base is selected from the group consisting of A, T, C and G, n is more than 1 to 20 or less and m is more than 3 to 20 or less.

7. The probe of claim 1, comprising one or more of the following sequences:

SEQ ID NO: 2: TAAGATAAC[C-FAM]CCGCACGTG (CT PB1-FAM internal),

SEQ ID NO: 4: GCGAACATA [C-ALEXA546] CAGCTATGATCAA (GC porA7-joe loopF), or

SEQ ID NO: 5: ATGTTCA [C-JOE] CATGGCGGAG (GC glnA7-ALEXA546 loopB).

8. The probe of claim 1, wherein the target nucleic acid is from a micro-organism, fungi, yeast or virus.

9. The probe of claim 1, wherein the probe is configured to be used in loop-mediated isothermal nucleic acid amplification.

10. A method of detecting a target nucleic acid sequence in a sample, the method comprising:

amplifying a target nucleic acid in the sample to provide an amplified nucleic acid;

probing the amplified nucleic acid with a probe as claimed in claim 1; and

detecting the presence of the target nucleic acid, wherein an increases in fluorescence of the probe indicates the presence of the target nucleic acid in the sample.

11. The method of claim 10, wherein the target nucleic acid is from a micro-organism, fungi, yeast or virus.

12. The method of claim 10, wherein the target nucleic acid is from Chlamydia trachomatis or Neisseria gonorrhoeae.

13. A method of diagnosing Chlamydia and/or Gonorrhea infection in a patient, the method comprising

providing a sample derived from the patient;

adding one or more probes of claim 1 to the sample; and

detecting the presence of a nucleic acid derived from Chlamydia trachomatis and/or Neisseria gonorrhoeae, wherein an increase in the fluorescence of the probe indicates the presence of a Chlamydia trachomatis and/or Neisseria gonorrhoeae infection.

14. The method of claim 13, wherein a single type of probe specific for a nucleic acid from either Chlamydia trachomatis or Neisseria gonorrhoeae is added to the sample.

15. The method of claim 13, wherein at least two different probes are added to the sample wherein a first probe is labelled with a first fluorescent label and is specific for probing Chlamydia trachomatis nucleic acid and a second probe is labelled with a different fluorescent label to the first probe and is specific for probing Neisseria gonorrhoeae nucleic acid.

16. The method of claim 10, wherein the probes are provided in a buffer system comprising dNTPs at a concentration of from 1-10 mM, one or more salts at a concentration of each salt of from 2-20 mM, Tris pH8.8 at a concentration of from 10-100 mM, Trehalose at a concentration of from 10-100 mM, BST polymerase at an amount of from 1 U-12 U and 0.01%-1% 1,2 propanediol.

17. The method of claim 16, wherein the one or more salts are selected from the group consisting of KCl, (NH4)2SO4 and MgSO4.

18. A kit for detecting a target nucleic acid comprising a probe as claimed in claim 1, a loop-mediated isothermal amplification reagent a buffer, an enzyme, dNTPs and one or more loop-mediated isothermal amplification primers.

19. The kit of claim 18, further comprising a positive and negative control.

20. The kit of claim 18, wherein the reagent buffer comprises dNTPs at a concentration of from 1-10 mM, one or more salts at a concentration of from 2-20 mM, Tris pH8.8 at a concentration of from 10-100 mM, Trehalose at a concentration of from 10-100 mM, BST polymerase at an amount of from 1 U-12 U and 0.01%-1% 1,2 propanediol.

21. The kit of claim 20, wherein the one or more salts are selected from the group consisting of KCl, (NH4)2SO4 and MgSO4.

22. The probe of claim 4, wherein the fluorophore is FAM, Joe or Alexa546.

Resources

Images & Drawings included:

Sources:

Similar patent applications:

Recent applications in this class: